摘要
Abstract
Objective:To evaluate the efficacy and safety of Olanzapine combined Shuganjieyu capsule in the treatment of schizophrenia. Methods: Fifty-seven patients with schizophrenia were randomly divided into two groups: Olanzapine combined Shuganjieyu capsule for the study group (n =29) and the Olanzapine for the control group (n=28), before treatment and after treatment (2,4,6,8) weekend, used positive and negative symptom scale (PANSS) and treatment emergent symptoms scale (TESS) to evaluate the efficacy and side effects. Results:The second week of the study group the total score, positive and negative symptoms, general pathology was significantly lower than before treatment, that in the control group at 4 weeks onset. The study group score of negative symptoms was significantly lower than the control group after 2 weeks. The positive symptoms and general psychopathology symptoms score of the two groups have no difference through all the treatment process. The use of Olanzapine dose in the study group was significantly lower than the control group.Conclusions:Olanzapine combined Shuganjieyu capsule for schizophrenia have a rapid onset, good efficacy and few side effects, and reduce the dose of Olanzapine.关键词
奥氮平/舒肝解郁胶囊/精神分裂症Key words
Olanzapine/Shuganjieyu capsule/Schizophrenia分类
医药卫生
